HC Wainwright restated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research report sent to investors on Friday, Benzinga reports. They currently have a $29.00 price target on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2025 earnings at ($0.52) EPS and Q4 2025 earnings at ($0.53) EPS.
Several other analysts also recently issued reports on the company. Chardan Capital restated a buy rating on shares of Immunovant in a research note on Monday, July 10th. Stifel Nicolaus upped their target price on Immunovant from $28.00 to $34.00 and gave the company a buy rating in a research report on Tuesday, July 18th. Guggenheim upped their target price on Immunovant from $30.00 to $32.00 in a research report on Tuesday, May 23rd. Citigroup upped their target price on Immunovant from $28.00 to $33.00 and gave the company a buy rating in a research report on Friday. Finally, Wells Fargo & Company upped their target price on Immunovant from $27.00 to $33.00 and gave the company an overweight rating in a research report on Monday, July 24th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $27.92.
Check Out Our Latest Stock Report on IMVT
Immunovant Price Performance
Immunovant (NASDAQ:IMVT – Get Free Report) last released its quarterly earnings results on Monday, May 22nd. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.05). Equities analysts anticipate that Immunovant will post -1.77 earnings per share for the current fiscal year.
Insider Transactions at Immunovant
In other news, CEO Peter Salzmann sold 101,339 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $21.73, for a total transaction of $2,202,096.47. Following the completion of the transaction, the chief executive officer now owns 1,129,797 shares of the company’s stock, valued at approximately $24,550,488.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Immunovant news, CEO Peter Salzmann sold 101,339 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $21.73, for a total value of $2,202,096.47. Following the completion of the transaction, the chief executive officer now owns 1,129,797 shares of the company’s stock, valued at approximately $24,550,488.81. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Mark S. Levine sold 3,917 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $21.63, for a total value of $84,724.71. Following the completion of the transaction, the insider now directly owns 326,774 shares of the company’s stock, valued at approximately $7,068,121.62. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,110 shares of company stock valued at $2,458,197. Corporate insiders own 4.80% of the company’s stock.
Institutional Investors Weigh In On Immunovant
A number of institutional investors have recently made changes to their positions in IMVT. FMR LLC grew its position in shares of Immunovant by 66.7% in the 1st quarter. FMR LLC now owns 4,146,969 shares of the company’s stock valued at $64,319,000 after buying an additional 1,658,836 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Immunovant by 281.2% in the first quarter. Federated Hermes Inc. now owns 1,903,894 shares of the company’s stock worth $10,491,000 after acquiring an additional 1,404,404 shares in the last quarter. Cowen AND Company LLC bought a new position in Immunovant in the fourth quarter worth approximately $22,188,000. Perceptive Advisors LLC raised its stake in shares of Immunovant by 761.2% in the first quarter. Perceptive Advisors LLC now owns 1,291,858 shares of the company’s stock worth $20,037,000 after purchasing an additional 1,141,858 shares during the last quarter. Finally, State Street Corp increased its position in shares of Immunovant by 27.5% during the first quarter. State Street Corp now owns 3,967,605 shares of the company’s stock valued at $61,538,000 after acquiring an additional 854,662 shares during the last quarter. Institutional investors own 44.67% of the company’s stock.
Immunovant Company Profile
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
Read More
- Five stocks we like better than Immunovant
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- MarketBeat Week in Review – 8/7 – 8/11
- The Dividend Kings With Highest Yield
- 3 Retailers To Watch Closely Next Week
- Stock Sentiment Analysis: How it Works
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
